Aspirin reduces lipopolysaccharide-induced pulmonary inflammation in human models of ARDS.

ABSTRACT:

Rationale

Platelets play an active role in the pathogenesis of acute respiratory distress syndrome (ARDS). Animal and observational studies have shown aspirin's antiplatelet and immunomodulatory effects may be beneficial in ARDS.

Objective

To test the hypothesis that aspirin reduces inflammation in clinically relevant human models that recapitulate pathophysiological mechanisms implicated in the development of ARDS.

Methods

Healthy volunteers were randomised to receive placebo or aspirin 75  or 1200 mg (1:1:1) for seven days prior to lipopolysaccharide (LPS) inhalation, in a double-blind, placebo-controlled, allocation-concealed study. Bronchoalveolar lavage (BAL) was performed 6 hours after inhaling 50 µg of LPS. The primary outcome measure was BAL IL-8. Secondary ou

SUBMITTER: Hamid U 

PROVIDER: S-EPMC5858553 | biostudies-literature | 2017 Nov

REPOSITORIES: biostudies-literature